Methotrexate: Optimizing the Efficacy in Rheumatoid Arthritis

Therapeutic Advances in Musculoskeletal Disease

Volumn 3, Issue 3, 2011, Pages 151-158

  Braun, Jürgen ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

combination therapy; DMARDs; methotrexate; monotherapy; rheumatoid arthritis; therapeutic strategies

Indexed keywords

ABATACEPT; ADALIMUMAB; AUROTHIOMALATE; AZATHIOPRINE; CERTOLIZUMAB; CHLOROQUINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; GLUCOCORTICOID; GOLD DERIVATIVE; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 6 RECEPTOR; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG WITHDRAWAL; HUMAN; JOINT RADIOGRAPHY; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

EID: 80053204647     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11408635     Document Type: Review

References (44)

1. Alarcon G.S. Bartolucci A.A. (2000) Radiographic assessment of disease progression in rheumatoid arthritis patients treated with methotrexate or minocycline. J Rheumatol 27: 530–534.
2. Aletaha D. Smolen J.S. (2002) Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 29: 1631–1638.
3. Bartelds G.M. de Groot E. Nurmohamed M.T. Hart M.H. van Eede P.H. Wijbrandts C.A. et al (2010) Surprising negative association between IgG 1 allotype disparity and anti-adalimumab formation: A cohort study. Arthritis Res Ther 12: R221. Epub 27 December 2010.
4. Becker M.L. van Haandel L. Gaedigk R. Lasky A. Hoeltzel M. Stobaugh J. et al (2010) Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: Effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis Rheum 62: 1803–1812.
5. Braun J. (2010) Optimal administration and dosage of methotrexate. Clin Exp Rheumatol 28: S46–S51.
6. Braun J. Kastner P. Flaxenberg P. Wahrisch J. Hanke P. Demary W. et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58: 73–81.
7. Burmester G.R. Feist E. Kellner H. Braun J. Iking-Konert C. Rubbert-Roth A. (2010) Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: The first phase IIIb real-life study (Tamara). Ann Rheum Dis 70: 755–759.
8. Calguneri M. Pay S. Caliskaner Z. Apras S. Kiraz S. Ertenli I. et al (1999) Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 17: 699–704.
9. Drosos A.A. Tsifetaki N. Tsiakou E.K. Timpanidou M. Tsampoulas C. Tatsis C.K. et al (1997) Influence of methotrexate on radiographic progression in rheumatoid arthritis: A sixty-month prospective study. Clin Exp Rheumatol 15: 263–267.
10. Dervieux T. Zablocki R. Kremer J. (2010) Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford) 49: 2337–45. Epub 16 August 2010.
11. Edmundson W.F. Guy W.B. (1958) Treatment of psoriasis with folic acid antagonists. AMA Arch Derm 78: 200–203.
12. Elliott M.J. Maini R.N. Feldmann M. Kalden J.R. Antoni C. Smolen J.S. et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (Ca2) versus placebo in rheumatoid arthritis. Lancet 344: 1105–1110.
13. Emery P. Breedveld F.C. Lemmel E.M. Kaltwasser J.P. Dawes P.T. Gomor B. et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39: 655–665.
14. Gubner R. August S. Ginsberg V. (1951) Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 221: 176–182.
15. Hoekstra M. Haagsma C. Neef C. Proost J. Knuif A. van de Laar M. (2006) Splitting high-dose oral methotrexate improves bioavailability: A pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 33: 481–485.
16. Jamnitski A. Bartelds G.M. Nurmohamed M.T. van Schouwenburg P.A. van Schaardenburg D. Stapel S.O. et al (2011) The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 70: 284–288.
17. Jeurissen M.E. Boerbooms A.M. van de Putte L.B. Doesburg W.H. Lemmens A.M. (1991) Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Ann Intern Med 114: 999–1004.
18. Jeurissen M.E. Boerbooms A.M. van de Putte L.B. Doesburg W.H. Mulder J. Rasker J.J. et al (1991) Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. a forty-eight-week randomized, double-blind trial. Arthritis Rheum 34: 961–972.
19. Jundt J.W. Browne B.A. Fiocco G.P. Steele A.D. Mock D. (1993) A comparison of low dose methotrexate bioavailability: Oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 20: 1845–1849.
20. Kremer J.M. (2010) Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 62: 3130.
21. Kremer J.M. Genovese M.C. Cannon G.W. Caldwell J.R. Cush J.J. Furst D.E. et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137: 726–733.
22. Kremer J.M. Lee J.K. (1986) The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 29: 822–831.
23. Lovell D.J. Giannini E.H. Reiff A. Cawkwell G.D. Silverman E.D. Nocton J.J. et al (2000) Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342: 763–839
24. Maini R.N. Breedveld F.C. Kalden J.R. Smolen J.S. Furst D. Weisman M.H. et al (2004) AntiTumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50: 1051–1065.
25. Maxwell L.J. Singh J.A. (2010) Abatacept for rheumatoid arthritis: A Cochrane systematic review. J Rheumatol 37: 234–245.
26. Mease P.J. (2011) Certolizumab pegol in the treatment of rheumatoid arthritis: A comprehensive review of its clinical efficacy and safety. Rheumatology 50: 261–270.
27. Morassut P. Goldstein R. Cyr M. Karsh J. Mckendry R.J. (1989) Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis–a randomized, double blind 26-week trial. J Rheumatol 16: 302–306.
28. Morgan S.L. Baggott J.E. (2010) Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 28: S102–S109.
29. Mottonen T. Hannonen P. Leirisalo-Repo M. Nissila M. Kautiainen H. Korpela M. et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. Fin-Raco Trial Group. Lancet 353: 1568–1573.
30. Nam J.L. Winthrop K.L. van Vollenhoven R.F. Pavelka K. Valesini G. Hensor E.M. et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69: 976–986.
31. O'dell J.R. Haire C.E. Erikson N. Drymalski W. Palmer W. Eckhoff P.J. et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334: 1287–1291.
32. Oguey D. Kolliker F. Gerber N.J. Reichen J. (1992) Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 35: 611–614.
33. Pincus T. Cronstein B. Braun J. (2010) Methotrexate–the anchor drug–an introduction. Clin Exp Rheumatol 28: S1–S2.
34. Rau R. (2010) Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. Clin Exp Rheumatol 28: S58–S64.
35. Rau R. Herborn G. Karger T. Menninger H. Elhardt D. Schmitt J. (1991) A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheumatol 18: 328–333.
36. Rau R. Herborn G. Menninger H. Sangha O. (1998) Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 37: 1220–1226.
37. Robbins L. MacIary S. Ostrov B. Ferriss J. (1997) Methotrexate use in rheumatic diseases: Comparison of efficacy and tolerance of oral, intramuscular and subcutaneous methods of administration. Arthritis Rheum 40: 1192.
38. Rozin A. Schapira D. Balbir-Gurman A. Braun-Moscovici Y. Markovits D. Militianu D. et al (2002) Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 61: 756–757.
39. Smith J.M. Cosulich D.B. Hultquist M.E. Seeger D.R. (1948) The chemistry of certain pteroylglutamic acid antagonists. Trans N Y Acad Sci 10: 82–83.
40. Suarez-Almazor M.E. Fitzgerald A. Grace M. Russell A.S. (1988) A randomised controlled trial of parenteral methotrexate compared with sodium aurothiomalat (Myochrysine) in the treatment of rheumatoid arthritis. J Rheumatol 15: 753–756.
41. Tak P.P. Rigby W.F. Rubbert-Roth A. Peterfy C.G. van Vollenhoven R.F. Stohl W. et al (2010) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The Image trial. Ann Rheum Dis 70: 39–46.
42. van der Heijde D. Breedveld F.C. Kavanaugh A. Keystone E.C. Landewe R. Patra K. et al (2010) Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of premier. J Rheumatol 37: 2237–2246.
43. Weinblatt M.E. Kaplan H. Germain B.F. Merriman R.C. Solomon S.D. Wall B. et al (1990) Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. a thirty-six-week, double-blind trial. Arthritis Rheum 33: 330–338.
44. Weinblatt M.E. Kremer J.M. Coblyn J.S. Maier A.L. Helfgott S.M. Morrell M. et al (1999) Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 42: 1322–1328.